Madrigal's Rezdiffra hits $1.1B as the company buys into MASH genetics
First-to-market MASH player in-licenses a PNPLA3 siRNA, revises gross-to-net favorably, and leans into GLP-1 combination ahead of an F4C readout.
MDGL · Earnings Call · 2026-05-06
Blockbuster, and still early
Madrigal reported a Q1 that was, by almost any standard, launch-defining — but the headline is not just the revenue. Rezdiffra's trailing-twelve-month net sales crossed $1.1 billion, and Q1 2026 net sales of $311 million grew 127% year over year. The more consequential change sits upstream: Madrigal is repositioning itself from a single-asset commercial story into a multi-program, genetically targeted MASH franchise, anchored by a new in-license it announced the day before the call.
CEO Bill Sibold was unambiguous about the milestone:
Rezdiffra has achieved blockbuster status generating more than $1.1 billion in net sales in the last 12 months. That's a $1 billion run rate in a market that's still in its infancy.
The market math supports the claim: the U.S. addressable diagnosed F2/F3 population under specialist care grew nearly 50% in two years — from 315,000 to 460,000 patients — while Rezdiffra penetration remains under 10% and the diagnosis rate just over 10%. Patient adds have been steady, ending Q1 with more than 42,250 active patients, 2.5x the year-ago level. F2 F3 MASH prescribing remains a roughly 50-50 split, and Q2 momentum carried through: “as we exit April, it's been our best NBRx month since launch” — William Sibold, Chief Executive Officer · 2026-05-06. The MASH market is still in its earliest stages, which is exactly the point.
The genetics bet: ARO-PNPLA3 is the real change
The genuinely new development is the in-license of ARO-PNPLA3 from Arrowhead — a clinical-stage siRNA that has completed Phase I and, per the company, reduced liver fat by up to 46% at 12 weeks at the highest dose in PNPLA3 homozygotes. This is a strategic pivot, not a bolt-on: it moves Madrigal from single-mechanism thyroid-hormone-receptor-beta monotherapy toward a foundational-therapy-plus-genetically-tailored-combination model.
“And because we believe this is one of the most compelling opportunities in the industry, we've moved quickly to build the leading pipeline in MASH. We added to it yesterday with a new siRNA asset that targets a mutation in the PNPLA3 gene, a genetically validated driver of disease in a meaningful subset of patients.” — William Sibold, Chief Executive Officer · 2026-05-06
The PNPLA3 mutation (I148M homozygous) is carried by roughly 30% of F2/F3 MASH patients and is especially prevalent in Hispanic populations — with a materially higher risk of liver-related events. Dave Soergel framed the logic as validated targets, complementary biology, modality-agnostic, and the company has now assembled a pipeline of 10+ programs for under $300 million. The combination philosophy predates the deal — Soergel said on the November call the company was “looking at pretty much every mechanism of action to potentially combine with resmetirom where there's a good scientific rationale” — David Soergel, Chief Medical Officer · 2025-11-04. Now that survey has a concrete answer: this is the leading pipeline theme surfacing at peak momentum in the company's own keyword trajectory, after PNPLA3 and siRNA were the top gainers over the past two quarters. The ARO PNPLA3 $25M upfront hits in Q2 — and notably, this genetics angle appears nowhere in the market's curated global keyword list. It is entirely idiosyncratic to Madrigal.
GLP-1s as background therapy — a reprioritization
The other notable shift is the explicit framing of GLP-1s as a background therapy rather than a competitor. This echoes prior calls — in February, Sibold said “Wegovy is being used, but certainly not to the detriment of Rezdiffra” — William J. Sibold, Chief Executive Officer · 2026-02-19 — but the current call goes further, treating GLP-1 weight loss as a tailwind that could potentiate Rezdiffra's antifibrotic effect, which is precisely why Madrigal in-licensed its own oral GLP-1, MGL-2086, now entering Phase I.
“We're still seeing around 25% of patients that are concomitantly on GLP-1 with Rezdiffra. And we think that's going to increase.” — William Sibold, Chief Executive Officer · 2026-05-06
The bigger prize is F4C — well-compensated cirrhosis, roughly 245,000 additional patients, no approved therapies — which the company believes could double the opportunity for foundational therapy Rezdiffra. The MAESTRO outcomes trial in F4C remains on track for a 2027 readout, with events tracking in range of expectations.
Financials: GTN favorably evolves; profitability still ahead
The one concrete numeric revision: gross-to-net. Entering 2026, Madrigal guided to gross-to-net in the high 30s; after Q1 — where GTN came in better than anticipated — that is now mid-to-high 30s for the rest of 2026.
“We now expect our gross to net discount to be in the mid- to high 30s for the rest of 2026.” — Mardi Dier, Chief Financial Officer · 2026-05-06
That is a small but genuine positive in a market where GLP-1 pricing pressure is the external question. The balance sheet is adequate but tightening: Q1 ended with $817.9M cash (down from $988.6M at end-2025), and Effective Net Cash sits at $339M, down from $702M a year ago. Q1 net loss widened to $94.4M including the one-time BD charge; management reiterates profitability is inevitable but not in 2026.
The watch item is R&D intensity: R&D at $108.7M against $311M revenue — roughly a third of gross revenue reinvested into a 10-program pipeline while SG&A still scales. That is the deliberate trade: mega blockbuster cash funding a genetics-led moat, with an Oral GLP 1s program as the metabolic complement.
The stock, tellingly, has been flat since the report — 90-day return of -0.6%, in an 8.6% drawdown from its July high, after a long run that peaked in late December 2025. The market is waiting on F4C data; that is the next real catalyst, and the ruthless, efficient pipeline operating model is the supporting argument for why Madrigal compounds.